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ABSTRACT
MHC class I-restricted CTLs specific for antigens expressed by malig­
nant cells are an important component of immune responses against 
human cancer. Recently, in melanoma a number of melanocyte differ en- 
tiation antigens have been identified as potential tumor rejection antigens. 
In the present study, we show that by applying pcptide-Ioaded dendritic 
cells, induced by granulocyte-macrophagc colony-stimulating factor and 
interleukin 4 from peripheral blood monocytes of healthy donors, we were 
able to elicit melanoma-associated antigen-specific CTL in vitro. We dem­
onstrate the induction of CTLs directed against HLA-A2.1 presented 
epitopes derived from tyrosinase, gplOO, and Melan A/MÀRT-1. Apart 
from lysis of peptide-loaded target cells, these CTLs displayed reactivity 
with HLÀ-À2.1* melanoma tumor cell lines and cultured normal mela­
nocytes endogenously expressing the target antigen. These data indicate 
that these CTLs recognize naturally processed and presented epitopes and 
that precursor CTLs against melanocyte differentiation antigens are pres­
ent in healthy individuals. The ability to generate tumor-specific CTLs in 
vitro, using granulocyte-macrophage colony-stimulating factor/interleukin 
4-induced dendritic cells, illustrates the potential use of this type of 
antigen-presenting cells for vaccination protocols in human cancer.
INTRODUCTION
CTLs that recognize melanoma tumor cells in a T-cell receptor- 
mediated and MHC-restricted manner have been isolated from tumor- 
bearing patients (reviewed in Ref. 1). Using a genetic approach, Boon 
and colleagues (2-4) have succeeded in identifying a number of 
antigens recognized by antimelanoma CTLs. Apart from the tumor- 
specific MAGE-1 and -3 antigens (2, 4), they also identified the 
melanocyte lineage-specific tyrosinase protein as a target for melano­
ma-specific CTLs (3). Similarly, we identified the gplOO melanocyte- 
specific protein as a target antigen for melanoma tumor-infiltrating 
lymphocytes (5). Recently, two other melanocyte differentiation an­
tigens, Melan A/MART-1 and gp75, were identified as target antigens 
for antimelanoma CTLs (6-8).
Cox et a l (9) reported that a naturally processed gplOO peptide 
(amino acids 280-288), identified by tandem mass spectroscopy, 
could direct target cell lysis by HLA-A2.1-restricted antimelanoma 
CTL lines (9). We demonstrated that the gpl00-reactive TIL 1200 line 
is reactive with two other HLA-A2.1~presented gplOO-derived 
epitopes (amino acids 154-162 and 457-466; Refs. 10 and 11). 
Recently, two novel epitopes derived from gplOO were shown to 
direct target cell lysis by HLA-A2.1-restricted tumor-infiltrating lym­
phocytes (12). Furthermore, a number of peptides derived from the 
other melanocyte differentiation antigens, tyrosinase and Melan
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A/MART-1, have been identified as epitopes for HLA-A2.1-restricted 
antimelanoma CTLs (13, 14).
The array of epitopes derived from antigens commonly expressed 
in melanoma tumors now provide a rationale for initiating multitarget 
tumor vaccination studies. However, successful activation of CD8* 
cytolytic effector lymphocytes with antitumor reactivity is critically 
dependent on adequate presentation of the epitopes involved. DCs,3 
expressing high levels of MHC class I and II and costimulatory 
molecules, have been shown to be intimately involved in the gener­
ation of tumor-specific cellular immunity (15). Recently, a method 
has been developed to generate DCs from peripheral blood by cultur­
ing progenitor cells in the presence of GM-CSF and IL-4 (16). Thus, 
obtained DCs proved to be very potent stimulator cells as was dem­
onstrated by their capacity to induce allogenic and autologous mixed 
lymphocyte reactions (16). Furthermore, these cells are extremely 
well capable of processing and presenting antigen (17). Taken to­
gether, these GM-CSF/IL-4-induced DCs are attractive candidates for 
the induction of antitumor immune responses.
In the present study, we investigated whether, within the T-cell 
repertoire of healthy donors, precursor T lymphocytes are present with 
the capability of recognizing HLA-A2.1-presented peptides derived 
from the melanocyte differentiation antigens gp'100, tyrosinase, and 
Melan A/MART-1. We demonstrate the in vitro induction of tumor- 
reactive CTLs using DCs generated from peripheral blood monocytes 
after culture in the presence of GM-CSF and IL-4, as APCs. These 
results illustrate the potential use of this type of APC for vaccination 
protocols of human cancer.
MATERIALS AND METHODS
Cell Culture. HLA-A2.1+ melanoma lines BLM and BLM gplOO H2.3 
were cultured as described previously (5). Melanoma lines Mel 397 (HLA- 
A2.1~) and Mel 624 (HLA-A2.1+) were a kind gift from Dr. Y. Kawakami 
(National Cancer Institute, NIH, Bethesda, MD) and were grown as was 
reported previously (18), BLM and Mel 624 cells were screened for tyrosinase 
and Melan A/MART-1 mRNA expression by PCR using oligonucleotides 
5 ' -TTGGCAGATTGTCTGTAG C C-3 75 ' - AGG C ATTGTGC ATG CTGC- 
TT-3' and 5'-AGACGAAATGGATACAGAGC-375#-CATGATTAGTACT- 
GCTAGCG-3', as primer combinations respectively (the tyrosinase-specific 
PCR primer combination was a kind gift from Dr. N. Brouwenstein, University 
Hospital Leiden, Department of Clinical Oncology, Leiden, the Netherlands). 
COS-7 cells were grown m DMEM (GIBCO, Paisley, Scotland, United King­
dom) supplemented with 7.5% FCS (BioWhittaker, Verviers, Belgium). TAP- 
deficient (T X B) cell hybrid T2 cells (19) were maintained in Iscove’s 
medium (GIBCO) +  7.5% FCS. WEHI 164 clone 13 cells (20) were kindly 
provided by Dr. P. Coulie (Ludwig Institute for Cancer Research, Brussels, 
Belgium) and were grown in RPMI 1640 supplemented with 7.5% FCS, 
L-ghitamine (216 mg/liter), L-asparagine (36 mg/liter), and L-arginine (116 
mg/liter). Isolation of normal melanocytes from foreskin was performed ac­
cording to the method of Eisinger and Marko (21), with modifications as
3 The abbreviations used are: DC, dendritic cell; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IL, interleukin; PBMC, peripheral blood mononuclear cell; 
TNF, tumor necrosis factor; APC, antigen-presenting cell.
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described previously (22). Melanocytes from early passages were used in TNF 
release assays.
HLA-A2.1+ Lymphocytes. Healthy Caucasian volunteers were pheno- 
typed HLA-A2.1'f' by flow cytometry using monoclonal antibodies BB7.2 (23) 
and MA2.1 (24). After obtaining signed consent, the donors underwent leu- 
kapheresis, and PBMCs were isolated by Ficoll-Hypaque density gradient 
centrifugation. The cells were cryopreserved in aliquots of 4 X 107 PBMCs,
Peptides. For induction of CTLs and chromium release assays, peptides 
were synthesized with a free COOIi-terminal either by f-moc peptide chem­
istry using an ABIMED Multiple Synthesizer or by t-boc chemistry on a 
Biosearch SAM2 peptide synthesizer. All peptides were >90% pure as indi­
cated by analytical HPLC. Peptides were dissolved in DMSO and stored at 
-20°C
In Vitro CTL Induction. Using thawed PBMCs, DCs were generated as 
described by Romani et a l (16). PBMCs were resuspended at 4 X  10fi cells/ml 
in Iscove’s medium containing 5% FCS and were distributed in 6~well tissue 
culture plates (Costar, Badhoevedorp, the Netherlands) at 3 ml/well. After 2 h 
of incubation at 37°C, the nonadherent cells were washed away, and 3 ml 
Iscove’s medium containing 5% FCS supplemented with 800 units/ml GM- 
CSF (Schering-Plough, Amstelveen, the Netherlands) and 500 units/mJ IL-4 
(Schering-Plough) were added to the wells. After 5 days of incubation IL -la  
(Hoffman LaRoche Inc., Nutley, NJ) and IFN-y (Boehringer Ingelheim, Alk- 
maar, the Netherlands) were added to the medium at final concentrations of 50 
LAF units/ml and 150 units/ml, respectively, and the cells were transferred to 
an incubator at 30°C. One day later, the APCs were loaded with peptide 
according to the procedure described by Cells et a l (25), with slight modifi­
cations. The DCs were collected and resuspended at 5 X IQ6 cells/ml in 
Iscove’s medium without serum containing 40 ¿xg/ml peptide and 3 jxg/ml 
human j32-microglobulin (Sigma, St. Louis, MO) and were incubated at 30°C 
for 4 h. Subsequently, the peptide-loaded APCs were irradiated at 5000 rad, 
centrifuged, and resuspended in Iscove’s medium containing 5% pooled hu­
man AB+ serum. Autologous CD8+-enriched responder T-lymphocytes were 
prepared by adhering thawed PBMCs for 2 h and by subsequent depletion of 
the nonadherent fraction of CD4+ T cells using the anti-CD4 monoclonal 
antibody RIV-7 (26) and sheep antimouse IgG-coated magnetic beads (Dynal, 
Oslo, Norway). The resulting population consisted of approximately 60% 
CD8+ T cells and 10% remaining CD4+ T cells. At the onset of stimulation 
2 X 105 peptide-loaded DCs and 2 X 106 responder cells/well were cocultured 
in a 24-well tissue culture plate (Costar) in 2 ml Iscove’s medium containing 
5% human serum and 5 ng/ml IL-7 (Genzyme, Cambridge, MA).
On day 10 and weekly thereafter, the responder populations were restimu­
lated. Irradiated PBMCs (4 X 105/well) were incubated for 2 h in a 24-well 
plate, nonadherent cells were removed, and 0.5 ml serum free Iscove’s medium 
was added per well containing 20 jug/ml peptide and 2 jig/ml /32-microglobu­
lin. After 2 h of incubation, the peptide was removed and 106 responder cells 
were added to the wells in 1 ml medium. One day later, 1 ml medium was 
added containing IL-2 (Perkin Elmer/Cetus Corp., Emeryville, CA) and IL-7 at 
final concentrations of 10 units/ml and 5 ng/ml, respectively. Responder 
populations were tested for their specificity after at least four rounds of 
restimulation.
Transfection of COS-7 Cells. Transfection was performed using the 
DEAE-dextran-chloroquine method (27). Briefly, 9 X 10s semiconfluent 
COS-7 cells were transfected with 5 /xg pBJ!HLA-A2,lneo (11) alone or in 
combination with 5 jug pBIlgplOOneo (5). After 48 h of transfection COS-7 
cells were used as stimulator cells in TNF release experiments.
Chromium Release Assay. The melanoma tumor cells used as targets 
were incubated for 48 h with 50 units/ml IFN-7 . Chromium release assays 
were performed as described previously (5), Briefly, 10r> target cells were 
incubated with 100 juCi Na251Cr04 (Amersham, Bucks, United Kingdom) for 
1 h. Various amounts of effector cells were then added to 2 X 103 target cells 
in triplicate wells of U-bottomed microtiter plates (Costar) in a final volume of 
150 jllI. In peptide recognition assays, T2 target cells were preincubated with 
various concentrations of peptide for 90 min at 37°C in a volume of 100 ¡x 1 
prior to the addition of effector cells. After 5 h of incubation, a portion of the 
supernatant was harvested, and its radioactive content was measured.
TNF Release Assay. CTL responder cells (3 X  103) were incubated with 
either 3 X 104 melanoma tumor cells, 4 X 104 cultured normal melanocytes, 
or 2 X 104 transiently transfected COS-7 cells in 100 /¿I Iscove’s medium 
containing 5% human serum and 5 ng/ml IL-7. After 24 h, 50 /U of the
supernatant were harvested, and its TNF content was measured by testing its 
cytolytic effect on W EHI164 clone 13 cells (20) using a colorimetric assay, as 
described previously (28).
RESULTS
Induction of CTLs Recognizing Melanocyte Differentiation An­
tigen-derived Epitopes. To assess whether within the T-cell reper­
toire of healthy donors precursor T lymphocytes are present with the 
capability of recognizing melanocyte differentiation antigen-derived 
epitopes, we initiated in vitro cultures of peptide-loaded stimulator 
cells along with autologous responder T lymphocytes. As stimulator 
cells we used higly potent DCs. HLA-A2.1.+ DCs were generated 
using GM-CSF and IL-4 according to the procedure described by 
Romani et a l (16), These cells were loaded with 40 ¡xg/ml peptide, 
irradiated, and added to CD8-enriched T cells. The CTL cultures were 
initiated in the presence of IL-7. As peptides we used HLA-A2.1- 
presented epitopes derived from the melanocyte differentiation anti­
gens gplOO [amino acids 280-288, YLEPGPVTA (9)], tyrosinase 
[amino acids 369-377, YMNGTMSQV (13)], and Melan A/MART-1 
[amino acids 27-35, AAGIGILTV (14)].
At day 10, the responder populations were restimulated with irra­
diated adherent blood mononuclear cells pulsed with the appropriate 
peptide. After 24 h, IL-7 and IL-2 were added to the cultures. Prior to 
the second restimulation the responder populations were depleted for 
contaminating CD4'1* T lymphocytes (30-50%). The resulting cul­
tures consisted of >90% CD3+/CD8“h T lymphocytes (data not 
shown).
After two more rounds of restimulation, responder cells were tested 
for cytotoxic activity (Fig. 1). All three bulk CTL populations effi­
ciently lysed HLA-A2.1+ T2 target cells incubated with the relevant 
peptides, whereas only low background lysis was observed in the 
presence of an irrelevant peptide. CTLs directed against the gplOO 
280-288 epitope were particularly efficient in lysing target cells 
loaded with the YLEPGPVTA peptide (Fig. 2A). Peptide titration 
showed that half-maximal lysis for this CTL culture was obtained at 
a gplOO 280-288 peptide concentration of approximately 500 pM 
(Fig. 2#). These results demonstrate that peptide-specific CTL bulk 
cultures could be obtained with the described induction protocol.
Peptide-induced CTLs Display Reactivity with Melanocyte Dif­
ferentiation Antigen-expressing Cells. To address the question 
whether the CTL responder populations could also recognize endog­










gplOO CTL tyrosinase CTL Melan A/MART-1 CTL
Fig. 1. Peptide-specific reactivity of in vitro-induced melanocyte differentiation anti- 
gen-specific CTL cultures, Chromium-labeled HLA-A2.1.+ T2 target cells were preincu­
bated for 90 min with 1 jllm  of the indicated peptides. The different CTL cultures were 
added at an E:T ratio of 40:1. After 5 h of incubation, chromium release was measured. 
■ , T2 -1- YLEPGPVTA (gplOO 280-288); □ , T2 +  YMNGTMSQV (tyrosine 369-377); 
(W), T2 + AAGIGILTV (Melan A/MART-1 27-35).
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TNF production is HLA-A2.1 restricted and gplOO specific, we co­
transfected COS-7 cells with the HLA-A2.1 and gplOO-encoding 
cDNAs and used these cells to stimulate the anti-gplOO CTLs (Fig. 5). 
These double transfectants stimulated the bulk anti-gplOO CTLs to 
produce a significant level of TNF, while COS-7 cells transfected 
without DNA or with the HLA-A2.1-encoding plasmid alone failed to 
stimulate the CTLs. Therefore, we conclude that the anti-gplOO CTLs 
recognize the gplOO 280-288 epitope endogenously presented in
HLA-A2.1.
Since gplOO is expressed in all cells of the melanocytic lineage, one 
would predict that normal melanocytes are also recognized by the 
gplOO 280-288-specific CTLs, as was previously shown for patient- 
derived antimeianoma CTLs (5, 30). To investigate this, short-term 
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Fig. 2. Bulk anti-gplOO CTLs efficiently recognize T2 cells loaded with peptide 
YLEPGPVTA. Ay chromium-labeled T2 target cells were preincubated with 1 jum peptide. 
The anti-gplOO 280-288 CTL culture was then added at different E:T ratios. After 5 h of 
incubation, chromium release was measured, Peptides; • ,  gplOO 280—288 YLEPGPVTA; 
O, tyrosinase 369-377 YMNGTMSQV. B, chromium-labeled T2 target cells were pre- 
incubated witli various concentrations of gplOO 280—288 YLEPGPVTA peptide. The 
anti-gplOO 280-288 CTL culture was then added at an E:T ratio of 15:1, After 5 h of 
incubation, chromium release was measured.
release experiments now using HLA-A2.11" melanoma cell lines BLM 
and Mel 624 as targets. BLM cells have lost expression of the gplOO 
antigen, both at the protein and at the mRNA level (29). Furthermore, 
they lack expression of both ty rosinase and Melan A/MART-1 as was 
assessed by PCR (data not shown), In contrast, Mel 624 cells express 
all three antigens. As shown in Fig. 3A, all peptide-induced CTL 
cultures lysed the antigen-expressing Mel 624 cells, whereas no lysis 
was observed against antigen-negative BLM cells. These data show 
that the three different CTL cultures induced using peptide-loaded 
DCs, ail recognized native epitopes derived from gplOO, tyrosinase, 
and Melan A/MART-1 endogenously processed and presented by 
HLA-A2.14* Mel 624 cells. The finding that gplOO-expressing BLM 
transfectants were lysed by the anti-gplOO 280-288 CTL culture 
confirmed this notion (Fig. 3J3), and demonstrated that transfected 
BLM cells are able to process and present antigenic peptides.
In addition, we assayed TNF release by the anti-gplOO CTLs to 
demonstrate engagement of gp 100-specific T-cell receptors. Fig. 4 
clearly demonstrates that gplOO 280-288-specific CTLs are only 
triggered to secrete TNF by HLA-A2.14' melanoma tumor cells that 
express the gplOO antigen. These results confirm the data we obtained 
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Fig. 3. Peptide-induced melanocyte differentiation antigen-specific CTL cultures spe­
cifically lyse antigen-positive melanoma cells. A, chromium-labeled HLA-A2.1* BLM 
and Mel 624 melanoma cells were used as target cells. BLM cells lack expression of 
gplOO, tyrosinase, and Melan A/MART-1,. The different CTL cultures were added al an 
E:T ratio of 40:1. After 5 h of incubation, chromium release was measured. B, the 
anti-gplOO CTL culture was added at different E:T ratios to chromium-labeled BLM (O) 










Fig. 4. Recognition of HLA-A2.14' gplOO+ melanoma cells by anti-gplOO 280-288 
CTLs. The anti-gplOO CTL culture was cocultured in combination with different mela­
noma tumor cells. After 24 fi of incubation, a portion of the supernatant was harvested, and 
its TNF content was measured in a bioassay using WEHI 164 clone 13 cells.
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Fig. 5. Recognition of COS-7 ceils transfected with HLA-A2.1 and gplOO cDNA by 
anti-gplOO CTLs. Bulk anti-gplOO CTLs were added to the transfectants, and after 24 h 
of incubation, a portion of the supernatant was harvested, and its TNF content was 
measured in a bioassay using WEHI 164 clone 13 cells. As controls, COS-7 cells 
transfected without DNA or with HLA-A2.1 cDNA alone were tested.
tested for recognition by the anti-gplOO bulk CTL culture. Melano­
cytes used in this study all expressed the gplOO antigen to a similar 
extent (data not shown). As shown in Fig. 6, HLA-A2.14' melanocytes 
efficiently stimulated the anti-gplOO CTL, whereas HLA-A2.1-  
melanocytes failed to do so. Together, these results demonstrate that 
peptide-induced in vitro bulk CTL cultures recognize epitopes endo­
genously processed and presented by both antigen-positive HLA- 
A2.1+ melanoma tumor cells and transfectants as well as by short­
term cultured normal melanocytes.
DISCUSSION
In the present report, we demonstrate that HLA-A2.1-restricted 
CD8+ CTLs specific for three distinct melanocyte differentiation 
antigens can be induced from peripheral blood lymphocytes of healthy 
individuals. These CTLs were generated in vitro using peptide- 
pulsed dendritic cells induced from adherent PBMCs using GM-CSF 
and IL-4. The obtained bulk CTL populations directed against 
gplOO (YLEPGPVTA), tyrosinase (YMNGTMSQV), and Melan 
A/MART-1 (AAGIGILTV) displayed reactivity with HLA-A2.1+ 
melanoma tumor cells expressing these three antigens. These findings 
confirm and extend observations of other investigators who succeeded 
in generating peptide-specific CTLs capable of recognizing endog­
enously processed antigen using autologous B lymphoblast cells as 
stimulator cells (25, 31, 32). The amount of peptide needed for target 
cell recognition by the obtained CTLs in these studies was approxi­
mately 1 i im  (31, 32). Using DCs as stimulator cells, we show that 
gplOO 280-288-specific CTLs can be induced that require a compa­
rable amount of peptide.
The presence of CTLs in the T-cell repertoire of healthy donors 
capable of recognizing melanocyte differentiation antigens indicates 
that deletion of potential auto-antigen-reactive CTL precursors has not 
occurred. It may be that these precursor T lymphocytes have not yet 
encountered their antigen and exist in the periphery as ignorant T 
lymphocytes (33), In this case, the in vitro activation of melanocyte 
differentiation antigen-reactive CTLs reflects the induction of a pri­
mary immune response. Alternatively, such lymphocytes may have 
seen melanocyte-derived epitopes in vivo, resulting in an elevated 
precursor frequency. In this light the described in vitro CTL induction 
can be regarded as a secondary response. In vivo priming of melano­
cyte antigen-specific CTLs could be one of the causes of melanocyte 
destruction as is seen in part of the vitiligo patients. The elevated 
precursor frequency of melanocyte antigen-specific CTLs might ex­
plain the results of Rivoltini et al. (34), who were able to generate 
donor-derived Melan A/MART-l-specific CTLs by just pulsing PB­
MCs with peptide without applying specialized APCs. Therefore, it 
remains to be established whether the induced CTL reactivities de-
scribed here are primary immune responses or reflect weak secondary 
responses.
So far four melanocyte differentiation antigens have been identified 
as target antigens for antimelanoma CTLs. Adoptive transfer of tu­
mor-infiltrating lymphocyte populations containing CTL specificities 
for gplOO, tyrosinase, and gp75 resulted in objective tumor regression 
in melanoma patients (8, 10, 35). This suggests that patients may 
benefit from an immune response against these antigens. Apart from 
occasionally occurring vitiligo, no toxic side effects against normal 
tissues expressing these antigens, like retina and skin, were observed 
in these patients. The occurrence of T lymphocytes recognizing mel­
anocyte differentiation antigens within healthy donors, as demon­
strated by our study and by those of others (32, 34), indicates that the 
T-cell repertoire is capable of generating responses against these 
differentiation antigens. Moreover, with these results the two basic 
requirements for vaccinations well-characterized target antigens and 
the presence of precursor T lymphocytes capable of recognizing the 
target antigens, have been fulfilled. Therefore, melanocyte differen­
tiation antigens are attractive candidates for active immunotherapy in 
melanoma.
DCs have been shown to play a critical role in the initiation of 
cellular immune responses (15). Hence, it is tempting to speculate that 
administration of DCs may be effective in generating cellular tumor 
immunity in vivo. Thus, the laborious approach of adoptive transfer of 
tumor-specific CTLs might be circumvented. So far, in vitro CTL 
induction protocols using APCs and peptide were only successful 
when using autologous B lymphoblasts or DCs as APCs. Regarding 
the in vivo induction of tumor-reactive CTL using peptide-pulsed 
APCs, usage of autologous DCs may be preferable to usage of 
autologous B lymphoblasts because, in addition to their antigen- 
presenting capacity, DCs may be better equipped to migrate through­
out the body and home to the lymph nodes. Efficacy of peptide-pulsed 
DCs as APCs for the induction of antigen-specific CTLs in vivo was 
demonstrated in a murine setting using marrow-derived, in vitro- 
generated DCs (36). Until recently, the use of DCs as immunothera- 
peutical agents has been hampered by their low frequency, causing 
great difficulty to obtain sufficient amounts of pure DCs. However, 
with this recently developed method, it has become possible to gen­
erate sizable numbers of pure DCs by culturing progenitor cells in the 
presence of GM-CSF and IL-4 (16). We showed that using such DCs, 
CTL responses could be elicited in vitro directed against melanocyte 
differentiation antigen-derived epitopes» The next step would be to 
generate large amounts of DCs in vitro, expose them to antigen, and 
reinfuse them into patients. Concomitant administration of cytokines 
like GM-CSF and IL-2 may further support in vivo induction of tumor 
immunity. Although this promising immunotherapeutical concept 







Fig. 6, Recognition of HLA-A2.1+-cultured normal melanocytes by anti-gplOO CTLs. 
Bulk anti-gplOO CTLs were added to the transfectants, and after 24 h o f  incubation, a 
portion o f the supernatant was harvested, and its TNF content was measured in a bioassay 
using W EHI 164 clone 13 cells. Melanocytes from early passages were used, and 
IILA-A2.1 expression was assessed by flow cytometry using anti-l-ILA-A2 monoclonal 
antibodies MA2.1 and BB7.2,
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antigens in melanoma, a similar approach may be applicable to other 
solid tumors,
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